Scientists Develop New Strategy to Target KRAS-Driven Pancreatic Cancer
A study published in the journal Oncotarget by researchers at Florida A&M University suggests that a new class of experimental compounds may help slow the spread of pancreatic ductal adenocarcinoma, one of the deadliest forms of cancer. Instead of targeting the KRAS gene directly, the researchers developed an approach aimed at disrupting the abnormal signaling pathways controlled by KRAS, a gene that has long been considered difficult to treat with drugs.
Pancreatic ductal adenocarcinoma is frequently driven by mutations in the KRAS gene, which cause cells to grow uncontrollably. Although several KRAS-targeted therapies have recently been developed, many tumors eventually become resistant, prompting researchers to search for alternative treatment strategies.
Researchers Targeted KRAS Signaling Rather Than the Gene Itself
The research focused on experimental compounds known as polyisoprenylated cysteinyl amide inhibitors, or PCAIs. Rather than blocking a single KRAS mutation, these compounds are designed to interfere with several abnormal protein interactions that occur downstream of KRAS signaling.
By disrupting multiple pathways that cancer cells rely on for growth and movement, the researchers hope this approach could make it more difficult for tumors to develop resistance to treatment.
According to the authors, this broader strategy may help overcome one of the biggest limitations of existing KRAS-targeted drugs, which can lose effectiveness as tumors acquire additional mutations or activate alternative signaling pathways.
Laboratory Tests Showed Reduced Cancer Cell Movement
The researchers tested several PCAIs in pancreatic cancer cell lines carrying KRAS mutations. One compound, known as NSL-YHJ-2-27, produced the strongest effect on cancer cell movement, reducing cell migration by more than 90% even at relatively low concentrations.
Further analysis showed that the compounds altered gene activity within the cancer cells. Genes associated with suppressing tumor growth became more active, while genes involved in invasion and metastasis showed reduced activity, suggesting that PCAIs may influence multiple biological processes involved in cancer progression.
The Compounds Altered Cell Structure
The team also examined how the treatment affected the internal structure of cancer cells. PCAIs reduced the levels of proteins involved in cell movement and disrupted actin filaments, which provide structural support and help cells move through surrounding tissue.
As these structural components were altered, the cancer cells lost much of their ability to migrate and invade nearby tissue.
The researchers note that limiting invasion and metastasis is an important goal because the spread of cancer to other parts of the body is a major contributor to deaths from advanced pancreatic cancer and many other malignancies.
Three-Dimensional Tumor Models Revealed an Unexpected Effect
To better replicate real tumors, the researchers also tested the compounds in three-dimensional pancreatic cancer models grown in the laboratory. PCAIs again caused extensive cancer cell death and disrupted the tumor-like structures.
However, the underlying mechanism differed from what the researchers initially expected. Instead of simply suppressing cancer-promoting signaling pathways, the compounds appeared to overstimulate some of these pathways.
The researchers believe this excessive signaling may trigger a buildup of reactive oxygen species inside cancer cells, causing internal damage that ultimately leads to cell death. They emphasize that this unexpected mechanism requires further investigation.
More Research Is Needed Before Human Studies
The findings are currently limited to laboratory experiments using cultured cells and three-dimensional tumor models. No studies in animals or humans have yet evaluated whether PCAIs are safe, well tolerated, or effective in living organisms.
It also remains uncertain whether the same mechanisms that damage cancer cells could also affect healthy tissues.
Even so, the researchers say the ability of PCAIs to act against multiple KRAS mutations is encouraging. KRAS mutations are involved in approximately 30% of all solid tumors, including many pancreatic, colorectal, and lung cancers. A treatment capable of targeting several mutant forms of KRAS could therefore have broader applications across multiple cancer types.
The Florida A&M research team notes that earlier laboratory studies also suggested that PCAIs may be active against breast, lung, and prostate cancer cells carrying KRAS mutations. Their next objective is to evaluate the compounds in animal studies to better understand dosing, safety, and how they behave inside the body before any clinical trials in people can be considered.
As scientists continue to develop direct KRAS inhibitors and combination therapies, approaches such as PCAIs may offer another potential strategy for treating KRAS-driven cancers. Future studies will determine whether these experimental compounds can safely limit tumor spread and eventually become part of cancer treatment.
